Claire Peter-Bouix

Av. D'Ouchy 4
Lausanne, VD 1006, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Discovery of a novel series of selective macrocyclic PKCTheta inhibitors.

Discovery of a novel series of selective macrocyclic PKCTheta inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: October 18, 2023

Novel library synthesis of 3,4-disubstituted pyridin-2(1H)-ones via cleavage of pyridine-2-oxy-7-azabenzotriazole ethers under ionic hydrogenation conditions at room temperature.

Novel library synthesis of 3,4-disubstituted pyridin-2(1H)-ones via cleavage of pyridine-2-oxy-7-azabenzotriazole ethers under ionic hydrogenation conditions at room temperature.

Journal: Beilstein journal of organic chemistry

Published: October 21, 2020

Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.

Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.

Journal: ACS medicinal chemistry letters

Published: August 30, 2019

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.

Journal: Journal of medicinal chemistry

Published: April 13, 2018

Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.

Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.

Journal: Bioorganic & medicinal chemistry letters

Published: March 27, 2018

Intrinsic Property Forecast Index (iPFI) as a Rule of Thumb for Medicinal Chemists to Remove a Phototoxicity Liability.

Intrinsic Property Forecast Index (iPFI) as a Rule of Thumb for Medicinal Chemists to Remove a Phototoxicity Liability.

Journal: Journal of medicinal chemistry

Published: March 17, 2018

Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.

Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.

Journal: Bioorganic & medicinal chemistry letters

Published: March 12, 2018

Sulfoximines as potent RORγ inverse agonists.

Sulfoximines as potent RORγ inverse agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: January 22, 2018

Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.

Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.

Journal: ChemMedChem

Published: December 06, 2017

Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.

Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.

Journal: Bioorganic & medicinal chemistry

Published: May 29, 2017

Identification of novel TACE inhibitors compatible with topical application.

Identification of novel TACE inhibitors compatible with topical application.

Journal: Bioorganic & medicinal chemistry letters

Published: January 06, 2017

Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.

Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: September 20, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026